3 results
Approved WMOCompleted
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
Approved WMOCompleted
The purpose of the current study is to determine whether LHW090 displays the clinical safety and efficacy profile to support further development for resistant hypertension.
Approved WMOCompleted
Objective: To evaluate the anatomical success of MOCA versus RFA in treatment of symptomatic insufficient SSV.